Increased frequencies of CD11b+CD33+CD14+HLA‐DRlow myeloid‐derived suppressor cells are an early event in melanoma patients

Abstract

Myeloid‐derived suppressor cells (MDSC) are a heterogeneous cell population characterized by immunosuppressive activity. Elevated levels of MDSC in peripheral blood are found in inflammatory diseases as well as in malignant tumors where they are supposed to be major contributors to mechanisms of tumor‐associated tolerance. We investigated the frequency and function of MDSC in peripheral blood of melanoma patients and observed an accumulation of CD11b⁺CD33⁺CD14⁺HLA‐DR^low MDSC in all stages of disease (I–IV), including early stage I patients. Disease progression and enhanced tumor burden did not result in a further increase in frequencies or change in phenotype of MDSC. By investigation of specific MDSC‐associated cytokines in patients’ sera, we found an accumulation of IL‐8 in all stages of disease. T‐cell proliferation assays revealed that MDSC critically contribute to suppressed antigen‐specific T‐cell reactivity and thus might explain the frequently observed transient effects of immunotherapeutic strategies in melanoma patients.